AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer

July 1, 2015

-- Experienced Healthcare Finance Leader Joins Leadership Team to Help Drive Continued Growth --

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced the appointment of Andrew Hack, M.D., Ph.D., as chief financial officer. Dr. Hack brings to Editas a deep understanding of capital markets, strong relationships across the financial community and more than a decade of experience analyzing the successes and failures of biopharmaceutical companies.

Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering

Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering

June 25, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. today announced the pricing of its initial public offering of 7,430,555 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Seres Therapeutics. In addition, Seres Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,114,583 shares of common stock from the company at the public offering price.

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

June 24, 2015

 – Third IDH Mutant Inhibitor to Enter Clinical Trials –

– Brain Penetration and Pan-IDHm Inhibition Broaden Development Options for IDH Mutant-Positive Cancers, Including Gliomas –

BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811

BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811

June 23, 2015

− Collaboration with AstraZeneca results in second Accurin candidate to enter clinical development −

− Promising AZD2811 Data Demonstrating Tumor Growth Inhibition and Prolonged Drug Exposure Recently Presented at 2015 American Association of Cancer Research (AACR) Annual Meeting −

T2 Biosystems Presents Data From Two Studies Evaluating T2MR in Hemostasis at the International Society on Thrombosis and Haemostasis Annual Congress

T2 Biosystems Presents Data From Two Studies Evaluating T2MR in Hemostasis at the International Society on Thrombosis and Haemostasis Annual Congress

June 23, 2015

Rapid, Accurate Multiplex Results Achieved Using Low Blood Volumes on a Single Easy-to-Use Instrument

Joule Expands Intellectual Property on Direct Conversion of CO2 to Hydrocarbons

Joule Expands Intellectual Property on Direct Conversion of CO2 to Hydrocarbons

June 16, 2015

Bedford, Mass -- Joule, the pioneer of liquid fuels from recycled CO2, today announced the issuance of an additional patent on the direct, continuous production of hydrocarbon fuels – extending its ability to target the highest-value molecules of the petroleum distillation process and generate them on demand from sunlight and CO2.

U.S. Patent #9,034,629, issued on May 19, covers both the cyanobacterium and the process for directly converting CO2 into medium-chain alkanes, which are the molecular basis of diesel, jet fuel and gasoline.

Acceleron Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

Acceleron Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

June 15, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that new study findings involving the use of dalantercept to block the activin receptor-like kinase 1 (ALK1) pathway for the treatment of metastatic breast cancer were published in the June 15th issue (volume 75, #12) of Cancer Research, a journal of the American Association for Cancer Research.

Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors

Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors

June 11, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company developing a novel class of Ecobiotic® drugs designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that Dennis Ausiello, M.D., has been elected to the company’s board of directors. Dr.